Replimune Group, Inc. (REPL) - Q2 2025 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 2025. Replimune Group, Inc. is a clinical-stage biotechnology company developing oncolytic immunotherapies, primarily focusing on its lead candidate RP1 (vusolimogene oderparepvec) for advanced melanoma. The company operates as a single segment and has not yet generated revenue from product sales.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | Q2 2024 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Net Loss | $(83.1) million | $(53.1) million | $(169.8) million | $(106.8) million |
| Net Loss Per Share | $(0.90) | $(0.68) | $(1.85) | $(1.45) |
| Operating Expenses | $84.3 million | $58.9 million | $174.7 million | $116.3 million |
| R&D Expenses | $57.9 million | $43.4 million | $115.7 million | $86.4 million |
| SG&A Expenses | $26.4 million | $15.5 million | $59.0 million | $29.9 million |
| Cash & Short-term Investments | $323.6 million (as of Sept 30, 2025) | |||
| Long-term Debt (Net) | $47.2 million (as of Sept 30, 2025) | |||
| Accumulated Deficit | $1,118.4 million (as of Sept 30, 2025) |
Material Changes vs. Prior Period
- Increased Operating Loss: Net loss increased by $30.0 million (56%) for the quarter and $63.0 million (59%) year-to-date compared to the prior year periods.
- R&D Spend Surge: R&D expenses rose significantly, driven by the ramp-up of the IGNYTE-3 confirmatory Phase 3 trial for RP1 ($4.8 million increase in Q2) and increased enrollment in RP2 studies.
- SG&A Expansion: SG&A expenses increased by $10.9 million in Q2, primarily due to a $9.5 million increase in sales and marketing costs as the company prepares for a potential commercial launch of RP1.
- Cash Flow: Net cash used in operating activities increased to $158.2 million for the six months ended Sept 30, 2025, compared to $87.8 million in the prior year period.
Guidance, Outlook, and Risks
- Regulatory Status (RP1): Following a Complete Response Letter (CRL) from the FDA in July 2025 regarding the RP1 Biologics License Application (BLA), the company resubmitted the BLA on October 9, 2025. The FDA accepted the resubmission on October 20, 2025, setting a new PDUFA decision date of April 10, 2026.
- Liquidity Outlook: Management believes existing cash and short-term investments ($323.6 million) are sufficient to fund operations through at least the fourth quarter of 2026, assuming RP1 development remains viable and excluding potential revenue.
- Legal Proceedings: A class action lawsuit was filed in July 2025 alleging securities law violations following the FDA CRL. Additionally, the SEC initiated an investigation in September 2025 regarding the RP1 BLA. The company denies wrongdoing and is cooperating with the investigation.
- Internal Controls: The company disclosed material weaknesses in internal control over financial reporting related to IT general controls (change management, user access, and operations). Remediation plans are underway, but controls were deemed ineffective as of September 30, 2025.
- Debt Covenant: The company experienced a temporary breach of a financial covenant regarding unrestricted cash levels in Q2 2025 but obtained a waiver and rectified the position in the following month.
Investor Verification Checklist
- Verify the status of the FDA review for the resubmitted RP1 BLA and the implications of the April 10, 2026 PDUFA date.
- Monitor the progress of the SEC investigation and the class action litigation regarding the July 2025 CRL.
- Assess the timeline and cost of remediation for the identified material weaknesses in internal controls over financial reporting.
- Review the burn rate relative to the $323.6 million cash position to confirm the runway through late 2026.
- Track enrollment and data readouts for the IGNYTE-3 Phase 3 trial and the REVEAL study for RP2.